Breaking News, Financial News

Financial Report: Biogen 1Q

TECFIDERA revenues up 63%

Biogen
 
1Q Revenues: $2.6 billion (+20%)

1Q Earnings: $823 million (+71%)

Comments: Total multiple sclerosis product sales were $2.1 billion compared to $1.7 billion in 1Q14. TECFIDERA revenues were $825 million, up 63%. Interferon revenues, including AVONEX and PLEGRIDY, were flat at $755 million. TYSABRI revenues were $463 million, up 5%. Revenues relating to RITUXAN and GAZYVA from Biogen’s unconsolidated joint business arrangement were $331 million, up 11%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters